The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion
|ClinicalTrials.gov Identifier: NCT01310465|
Recruitment Status : Unknown
Verified January 2011 by Fudan University.
Recruitment status was: Recruiting
First Posted : March 8, 2011
Last Update Posted : March 8, 2011
|Condition or disease||Intervention/treatment||Phase|
|Image Changes of Lumbar Fusion Bone Turnover Markers Bone Mineral Density||Drug: zoledronic acid Drug: sodium chloride||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||December 2011|
|Estimated Study Completion Date :||April 2012|
Experimental: Experimental group
Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
Drug: zoledronic acid
zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
Placebo Comparator: Placebo Comparator
Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
Drug: sodium chloride
sodium chloride, 100ml, intravenous, one time at three days postoperatively
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01310465
|Contact: Chao Li, firstname.lastname@example.org|
|Zhongshan hospital of Fudan university||Recruiting|
|Shanghai, Shanghai, China, 200032|
|Contact: Chao Li, bachlor 15202183944 email@example.com|
|Principal Investigator: Chao Li, bachlor|